Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$1.8 million.

  • Pharma's Net Income towards Common Stockholders fell 605.71% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 4871.51%. This contributed to the annual value of -$7.1 million for FY2025, which is 4522.31% up from last year.
  • Latest data reveals that Pharma reported Net Income towards Common Stockholders of -$1.8 million as of Q3 2025, which was down 605.71% from -$1.6 million recorded in Q2 2025.
  • Pharma's Net Income towards Common Stockholders' 5-year high stood at -$1.2 million during Q1 2025, with a 5-year trough of -$6.5 million in Q1 2022.
  • In the last 5 years, Pharma's Net Income towards Common Stockholders had a median value of -$2.4 million in 2021 and averaged -$2.8 million.
  • As far as peak fluctuations go, Pharma's Net Income towards Common Stockholders plummeted by 16216.05% in 2021, and later skyrocketed by 6727.5% in 2024.
  • Over the past 5 years, Pharma's Net Income towards Common Stockholders (Quarter) stood at -$2.4 million in 2021, then grew by 5.54% to -$2.2 million in 2022, then crashed by 148.51% to -$5.6 million in 2023, then soared by 67.28% to -$1.8 million in 2024, then rose by 0.44% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.2 million during Q1 2025.